The Biopharma Report
Subscribe
Sign in
Home
Archive
About
New
Top
The Biopharma Report #013
Important Update, Novartis One Step Closer To Its Pluvicto Blockbuster Aspirations
Dec 9, 2022
•
The Biopharma Report
10
Share this post
The Biopharma Report #013
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
The Biopharma Report #012
AstraZeneca Acquires Neogene, Novartis Announces Promising Pluvicto Data
Dec 7, 2022
•
The Biopharma Report
7
Share this post
The Biopharma Report #012
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
J&J Drops New Data, Horizon Entertains Offers
The Biopharma Report #011
Dec 3, 2022
•
The Biopharma Report
12
Share this post
J&J Drops New Data, Horizon Entertains Offers
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
November 2022
The Biopharma Report #010
Regeneron Bets On Conditional Activation, Merck Acquires Imago
Nov 25, 2022
•
The Biopharma Report
14
Share this post
The Biopharma Report #010
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
The Biopharma Report #009
GSK and Pfizer Battle For RSV Supremacy, Alkermes Splits Into Two
Nov 7, 2022
•
The Biopharma Report
10
Share this post
The Biopharma Report #009
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
October 2022
The Biopharma Report #008
Lilly Enters The Hearing Loss Space, Gilead Strikes A Bispecific Antibody Deal
Oct 21, 2022
•
The Biopharma Report
189
Share this post
The Biopharma Report #008
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
August 2022
The Biopharma Report #007
$MRK $BMY $MRNA $SAN $GSK $ABBV $PFE $ALNY
Aug 21, 2022
•
The Biopharma Report
17
Share this post
The Biopharma Report #007
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
The Biopharma Report #006
$BIIB $RHHBY
Aug 1, 2022
•
The Biopharma Report
8
Share this post
The Biopharma Report #006
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
July 2022
The Biopharma Report #005
$RHHBY $REGN $ABBV $RGNX $NESN $MCRB
Jul 20, 2022
•
The Biopharma Report
11
Share this post
The Biopharma Report #005
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
The Biopharma Report #004
$SNY $ICPT
Jul 14, 2022
•
The Biopharma Report
8
Share this post
The Biopharma Report #004
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
June 2022
Pfizer’s Ibrance Disappoints: What’s Next?
Taking a Look at the CDK4/6 Inhibitors Landscape
Jun 13, 2022
7
Share this post
Pfizer’s Ibrance Disappoints: What’s Next?
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
December 2021
Agios Pharmaceuticals $AGIO
A Concise Look into the Company and its Upcoming Catalyst
Dec 26, 2021
9
Share this post
Agios Pharmaceuticals $AGIO
thebiopharmareport.substack.com
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts